Opinion
Published on 04 Jan 2023
Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1098375
- 13,380 views
- 4 citations
